Please provide your email address to receive an email when new articles are posted on . Dysregulated aldosterone production, sometimes driven by obesity, can cause hypertension. Targeted therapies ...

Lorundrostat, a novel therapy which blocks the production of aldosterone from the adrenal glands, demonstrated clinically meaningful and sustained reductions in blood pressure in 1,083 patients with ...

Mineralys Therapeutics is investing heavily in R&D for its lead candidate, lorundrostat, a treatment for hypertension and chronic kidney disease. R&D expenses nearly doubled from Q1 2022 to Q1 2023.

– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a ...

Mineralys Therapeutics announced the results of the Phase 3 Launch-HTN trial, the largest hypertension study involving an aldosterone synthase inhibitor, which included over 1,000 participants with ...

Single-nucleus RNA sequencing of 2 nonfunctional adenomas and 3 aldosterone-producing adenomas revealed 13 clusters (Upper). Pseudotime course analysis predicted the transition of two cell fates in ...

A novel treatment for hard-to-control high blood pressure has shown strong results in a major global clinical trial. The Phase 3 Launch-HTN study found that lorundrostat, an aldosterone synthase ...